Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma
Purpose: Some patients with cancer use herbal therapy as an adjunct while receiving conventional cancer treatments. Beta-glucans have direct cytotoxic effects on cancer cells as well as stimulatory effects on the immune system. In this study, a nutritional supplement containing 1,3-1,6 beta-glucan obtained from baker's yeast (Saccharomyces cerevisiae) was used by patients diagnosed with sarcoma, and this study aimed to retrospectively evaluate the effect of beta-glucan use on the incidence of neutropenic fever (NF) and survival rates. Materials and Methods: Among the patients diagnosed with sarcoma between 2014 and 2017, 27 patients who used beta-glucan were included in the beta-glucan group, and 31 patients who did not use beta-glucan were included in the control group. The clinical records of patients were retrospectively analyzed. Results: The number of patients who had NF and the mean length of hospital stay due to NF were higher in the beta-glucan group than those in the control group, but the results were not statistically significant. The overall survival rates at 5 years were 83.3% and 52.9% and event-free survival rates at 5 years were 48.1% and 71% in the beta-glucan and control groups, respectively. Conclusion: The effect of prophylactic beta-glucan use on the incidence of NF and survival rates in pediatric patients with sarcoma should be evaluated more reliably in further prospective studies on a large patient group..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Cukurova Medical Journal - 47(2022), 2, Seite 596-602 |
| Sprache: |
Englisch ; Türkisch |
|---|
| Beteiligte Personen: |
İbrahim Bayram [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Beta-glucan |
|---|
| doi: |
10.17826/cumj.1039267 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ044029608 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ044029608 | ||
| 003 | DE-627 | ||
| 005 | 20230503112801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.17826/cumj.1039267 |2 doi | |
| 035 | |a (DE-627)DOAJ044029608 | ||
| 035 | |a (DE-599)DOAJ33a857501a4e497b8daaf3c4fa5d2b7f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a tur | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a İbrahim Bayram |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose: Some patients with cancer use herbal therapy as an adjunct while receiving conventional cancer treatments. Beta-glucans have direct cytotoxic effects on cancer cells as well as stimulatory effects on the immune system. In this study, a nutritional supplement containing 1,3-1,6 beta-glucan obtained from baker's yeast (Saccharomyces cerevisiae) was used by patients diagnosed with sarcoma, and this study aimed to retrospectively evaluate the effect of beta-glucan use on the incidence of neutropenic fever (NF) and survival rates. Materials and Methods: Among the patients diagnosed with sarcoma between 2014 and 2017, 27 patients who used beta-glucan were included in the beta-glucan group, and 31 patients who did not use beta-glucan were included in the control group. The clinical records of patients were retrospectively analyzed. Results: The number of patients who had NF and the mean length of hospital stay due to NF were higher in the beta-glucan group than those in the control group, but the results were not statistically significant. The overall survival rates at 5 years were 83.3% and 52.9% and event-free survival rates at 5 years were 48.1% and 71% in the beta-glucan and control groups, respectively. Conclusion: The effect of prophylactic beta-glucan use on the incidence of NF and survival rates in pediatric patients with sarcoma should be evaluated more reliably in further prospective studies on a large patient group. | ||
| 650 | 4 | |a beta-glucan | |
| 650 | 4 | |a neutropenic fever | |
| 650 | 4 | |a pediatric sarcomas | |
| 650 | 4 | |a survival | |
| 650 | 4 | |a beta-glukan | |
| 650 | 4 | |a nötropenik ateş | |
| 650 | 4 | |a pediatrik sarkomlar | |
| 650 | 4 | |a sağkalım | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Gülay Sezgin |e verfasserin |4 aut | |
| 700 | 0 | |a Metin Çil |e verfasserin |4 aut | |
| 700 | 0 | |a Serhan Küpeli |e verfasserin |4 aut | |
| 700 | 0 | |a Ayşe Özkan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Cukurova Medical Journal |d Cukurova University, 2017 |g 47(2022), 2, Seite 596-602 |w (DE-627)DOAJ000132519 |x 26023040 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2022 |g number:2 |g pages:596-602 |
| 856 | 4 | 0 | |u https://doi.org/10.17826/cumj.1039267 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/33a857501a4e497b8daaf3c4fa5d2b7f |z kostenfrei |
| 856 | 4 | 0 | |u https://dergipark.org.tr/tr/download/article-file/2142985 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2602-3040 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2022 |e 2 |h 596-602 | ||